Cargando…

miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells

INTRODUCTION: Previous studies have found that miRNAs play a key role in drug resistance. Multiple reports show that miRNAs act as regulators in colorectal cancer (CRC) cells, but the role of miR-206 in CRC is still not well understood. The current study aimed to explore the potential function of mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xiaomin, Fu, Rao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881530/
https://www.ncbi.nlm.nih.gov/pubmed/29636622
http://dx.doi.org/10.2147/OTT.S159093
_version_ 1783311340408930304
author Meng, Xiaomin
Fu, Rao
author_facet Meng, Xiaomin
Fu, Rao
author_sort Meng, Xiaomin
collection PubMed
description INTRODUCTION: Previous studies have found that miRNAs play a key role in drug resistance. Multiple reports show that miRNAs act as regulators in colorectal cancer (CRC) cells, but the role of miR-206 in CRC is still not well understood. The current study aimed to explore the potential function of miR-206 in 5-FU resistance. METHODS: To indentify the role of miR-206 in 5-FU resistance, the expression of miR-206 was examined by real-time polymerase chain reaction (RT-PCR) in 5-FU-resistant (FR) CRC (HCT116/FR and RKO/FR) and their parental cell lines. miR-206 mimic was transfected to 5-FU-FR CRC, and the 5-FU sensitivity was detected by MTS and flow cytometry. Using miRNA target prediction software, we found that miR-206 could target the 3′ untranslated region (3′UTR) sequence of Bcl-2. RESULTS: miR-206 was found to be downregulated in 5-FU-FR CRC in comparison with their parental cell lines, suggesting its crucial relevance for colon cancer biology. Downregulation of miR-206 promoted drug resistance and decreased apoptosis of parental cells, while overexpression of miR-206 promoted drug cytotoxicity and apoptosis of HCT116/FR cells. We also identified miR-206 targeting Bcl-2 directly in CRC, which is required for miR-206 mediated-5-FU resistance. CONCLUSION: Our results show that miR-206 targets Bcl-2 to mediate chemoresistance, proliferation, and apoptosis in CRC. This study provides a novel promising candidate for colon cancer therapy.
format Online
Article
Text
id pubmed-5881530
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58815302018-04-10 miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells Meng, Xiaomin Fu, Rao Onco Targets Ther Original Research INTRODUCTION: Previous studies have found that miRNAs play a key role in drug resistance. Multiple reports show that miRNAs act as regulators in colorectal cancer (CRC) cells, but the role of miR-206 in CRC is still not well understood. The current study aimed to explore the potential function of miR-206 in 5-FU resistance. METHODS: To indentify the role of miR-206 in 5-FU resistance, the expression of miR-206 was examined by real-time polymerase chain reaction (RT-PCR) in 5-FU-resistant (FR) CRC (HCT116/FR and RKO/FR) and their parental cell lines. miR-206 mimic was transfected to 5-FU-FR CRC, and the 5-FU sensitivity was detected by MTS and flow cytometry. Using miRNA target prediction software, we found that miR-206 could target the 3′ untranslated region (3′UTR) sequence of Bcl-2. RESULTS: miR-206 was found to be downregulated in 5-FU-FR CRC in comparison with their parental cell lines, suggesting its crucial relevance for colon cancer biology. Downregulation of miR-206 promoted drug resistance and decreased apoptosis of parental cells, while overexpression of miR-206 promoted drug cytotoxicity and apoptosis of HCT116/FR cells. We also identified miR-206 targeting Bcl-2 directly in CRC, which is required for miR-206 mediated-5-FU resistance. CONCLUSION: Our results show that miR-206 targets Bcl-2 to mediate chemoresistance, proliferation, and apoptosis in CRC. This study provides a novel promising candidate for colon cancer therapy. Dove Medical Press 2018-03-29 /pmc/articles/PMC5881530/ /pubmed/29636622 http://dx.doi.org/10.2147/OTT.S159093 Text en © 2018 Meng and Fu. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Meng, Xiaomin
Fu, Rao
miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
title miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
title_full miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
title_fullStr miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
title_full_unstemmed miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
title_short miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
title_sort mir-206 regulates 5-fu resistance by targeting bcl-2 in colon cancer cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881530/
https://www.ncbi.nlm.nih.gov/pubmed/29636622
http://dx.doi.org/10.2147/OTT.S159093
work_keys_str_mv AT mengxiaomin mir206regulates5furesistancebytargetingbcl2incoloncancercells
AT furao mir206regulates5furesistancebytargetingbcl2incoloncancercells